Founded in 2010, Abionic developed its nanotechnology within the Swiss Federal Institute of Technology in Lausanne (EPFL). Already in 2012, Abionic obtained the ISO 13485 quality certification for research and development, production and marketing of products for the in-vitro diagnostics market and has successfully maintained its system since then. The company is benchmark in winning prices, 4 times best med-tech startup and many others. Abionic is now a scale up that has proven the functionality and value of its technology in the market and will grow not only its production capacities and test portfolio but also its international footprint.
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s portfolio of injectable treatments for diabetes, featuring five clinical-stage products and five preclinical products, is among the largest and most differentiated of the industry. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
CHEMOTHERAPEUTIC Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Additionally, an aqueous formulation of human glucagon (BioChaperone Human Glucagon) has recently entered clinical testing. Adocia is also developing two combinations of insulin glargine with GLP-1s, (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, termed TandAbs® because of their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells. Affimed’s TandAbs have the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture (which provides for four binding domains), the TandAbs bind to their targets with high affinity and have half-lives that allow intravenous administration. Affimed believes, based on the TandAbs mechanism of action and the preclinical and clinical data it has generated to date, that its product candidates may ultimately improve response rates, clinical outcomes and survival in cancer patients and could eventually become a cornerstone of modern targeted oncology care.
Affimed has focused its research and development efforts on three proprietary programs for which it retains global commercial rights. Because TandAbs bind with receptors that are known to be present on a number of types of cancer cells, each of Affimed’s TandAb product candidates could be developed for the treatment of several different cancers. Affimed intends to initially develop its two clinical stage product candidates in orphan or high-medical need indications, including development as a salvage therapy for patients who have relapsed after, or are refractory to, that is who do not respond to treatment with, standard therapies.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena’s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time. ALLN-177, Allena’s lead product candidate, is a first-in-class, oral enzyme therapeutic in late-stage clinical development for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels due to either a genetic defect (primary) or from hyper-absorption of oxalate from the diet (secondary). Secondary hyperoxaluria can be due to an undefined cause (idiopathic) or as a result of underlying GI disorders (enteric). Kidney stones, often the first sign of hyperoxaluria, are painful and may require interventional procedures, for example. Severe hyperoxaluria in settings of enteric and primary hyperoxaluria may also damage the kidney and potentially lead to chronic kidney disease and end-stage renal disease. There are currently no approved therapies for the treatment of hyperoxaluria. Allena has conducted a robust clinical development program of ALLN-177, including three Phase 2 clinical trials, which demonstrated reductions of urinary oxalate excretion in patients with secondary hyperoxaluria, especially in patients with enteric hyperoxaluria. ALLN-177 has also been well tolerated in clinical trials to date. Based on these data, the high unmet medical need, and the enzyme’s specific mechanism of action, Allena’ lead program is focused on adult patients with enteric hyperoxaluria. The FDA also has granted separate orphan drug designations for ALLN-177 for the treatment of primary hyperoxaluria and for the treatment of pediatric hyperoxaluria. In addition, the European Commission has granted orphan designation for ALLN-177 for the treatment of primary hyperoxaluria. ALLN-346, Allena’s second product candidate, is being developed for patients with hyperuricemia and moderate to severe CKD. Hyperuricemia, or elevated levels of uric acid in the blood is commonly associated with gout as well as kidney stones and kidney disorders.
Anagenesis is a preclinical‐stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs. A wide spectrum of diseases in which specific tissues are lost or damaged remain incurable. This reflects a lack of drugs to promote regeneration or of transplantable cells to replace those that are missing. One example of this urgent unmet need are the human conditions that lead to degeneration of skeletal muscle, ranging from muscular dystrophies and neuromuscular disease to muscle-wasting caused by disuse. However, to date, it has not been possible to generate muscle cells in sufficient quantity for high-throughput drug screening, or sufficient purity for cell-based therapy.
Patented new technologies licensed-in by Anagenesis have changed all this. Using stem cells as a renewable source, Anagenesis scientists first generated the natural embryonic precursors of skeletal muscle then devised protocols for turning the precursors into contractile muscle fibers in the culture dish. The resulting muscle cells are purer and more abundant than any before and successfully colonize damaged muscle when transplanted in vivo. Moreover, when stem cells from mice with muscle disorders are used, the resulting muscle fibers show characteristic disease-related defects in culture. The time is therefore ripe for drug screening to enhance muscle regeneration and/or correct disease phenotypes, and for a reasoned approach to therapeutic muscle reconstruction. Anagenesis has exclusive rights to two key patents from the French national biomedical research agency INSERM. Two main activities will generate revenues: a) Cell therapy for genetic muscle disorders b) Cell-based screening of small molecules
Anagenesis already secured its first private funding from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area.
Anima Biotech is pioneering Translation Control Therapeutics, a new class of drugs that control protein translation. Our novel drug discovery platform enables a new therapeutic strategy to approach hard or undruggable protein targets where existing methods have failed for decades.
Our platform is enabled by a breakthrough, patented technology. Anima's Protein Synthesis Monitoring (PSM) technology enables for the first time the visualization and monitoring of protein synthesis by ribosomes in living cells in real time. We use this information in specialized high content screening methods to discover molecules that regulate protein translation, correcting problems in over-expression or under-expression of target proteins. The platform is the result of over a decade of development in collaboration with a broad network of 17 leading academia and research institutions that have validated and expanded the scope and reach of our technology. Anima's drug discovery pipeline is currently focused on four outstanding therapeutic areas where the underlying cause of the disease is closely linked to protein translation: Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (controlling the production of toxic proteins).
Protein translation is a major biological process and the ability to control it opens a new therapeutic strategy for many additional diseases. We seek to maximize the therapeutic potential of our platform by partnering with pharma companies in their drug discovery programs.
Aptose Biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. Aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. In the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies.
Biosceptre is a UK headquartered biotech developing next-generation cancer therapeutics utilising its proprietary target, nfP2X7. Biosceptre has an experienced team of scientists and executives based in state of the art facilities at the Babraham Research Campus, Cambridge UK and at Sydney Australia.
Biosceptre has multiple clinical programs designed to exploit nfP2X7 via a range of modalities including systemic antibodies, vaccines and topical therapeutics. A’s comprehensive global IP portfolio covers broadly both the target itself and multiple drug modalities, as well as multiple candidates designed to exploit nfP2X7.
Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.
Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cantargia specialises in antibody-based cancer treatment. CAN04, the company's patented antibody treatment, has a dual mechanism of action. CAN04 fights cancer by activating the immune system and blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immuno-oncology.
Potential for several cancer diseases Cantargia is developing antibody-based treatments specifically targeting the molecule IL1RAP with a potential to treat a number of different cancers. The lead candidate, CAN04, is initially focused on non-small cell lung cancer (NSCLC) and pancreatic cancer and clinical trials started in 2017. The aim is to develop a new drug with the potential to become an important part of future cancer treatment.
Our product candidate CAN04 CAN04 is designed to block the cancer cell's signalling via the interleukin-1 system. Thereby counteracting the tumour inflammation that facilitates growth and protection of the tumour. CAN04 is also designed to stimulate the body's immune system to eliminate cancer cells directly.
Project CANxx Cantargia has started development of a new antibody against IL1RAP which will also be subject for patent protection. The new antibody is being designed for treatment of autoimmune and inflammatory diseases, with the aim to have a product candidate selected during 2019.
Background Cantargia AB was founded in 2009/2010 based on a discovery made by Professor Thoas Fioretos and Dr Marcus Järås at Lund University. Their research showed that leukaemic stem cells express a protein, IL1RAP, on the cell surface which is not expressed to the same extent on normal stem cells. Cantargia's research has since then shown that IL1RAP is also expressed in a range of solid tumour cancers.
IL1RAP is important for the cancer cells' ability to create a favourable environment for proliferation and expansion and antibodies targeting IL1RAP could potentially be used to treat several different forms of cancer, but also autoimmune and inflammatory diseases.
The CLINUVEL story starts in 1987 when university researchers launched an idea of synthesising human hormones to protect the skin. During this period, little was known about the properties of alpha-MSH (melanocyte stimulating hormone), although the scientists had discovered the biomimicry which these hormones could evoke (providing a golden glow without sun exposure). A basis was laid, but the majority of the research & development work was ahead to actually build a relevant product and successful company around this beginning scientific idea.
The CLINUVEL team in Australia obtained the rights to the technologies and established a company around alpha-MSH, its derivatives and knowledge. With an unabating focus and unusual willpower the CLINUVEL teams charged ahead and developed innovative technology which would release the hormonal analogue in picograms (10¯¹² grams) per day in a controlled fashion. With the world’s first dissolvable implant releasing a novel hormone to mimic the effects of the sun on human skin but without incurring the photo damage, our teams worked for two decades to test the technology - SCENESSE® - in more than 1,400 patients worldwide through 4,500 doses. Innovation came with rigid testing.
In 2014, the European Medicines Agency and the European Commission approved SCENESSE® as the world’s first photo protective drug for market authorisation to be distributed to European patients treated by specialist hospitals, dermatologists and other specialists. What had once been thought of as science fiction had become reality in October 2014, when SCENESSE® became the first systemic drug providing protection to the entire skin surface without exposure to light and UV. Currently, the Food and Drug Administration is reviewing the innovative pharmaceutical product for release in the United States. At CLINUVEL we focussed and specialised for two decades on extreme disorders which were provoked by environmental conditions, such as erythropoietic proto- and congenital porphyria [EPP, CEP], Solar Urticaria and other light-induced diseases. Worldwide the erythropoietic protoporphyria patients are forced to live an indoors existence deprived of any light source.
We are a global speciality pharmaceutical company, continuously striving to confront current gaps in patient care. Our ambition drives us to deliver medical treatments that deliver real change to improve patients lives wherever they are needed in the world.
Exogenus Therapeutics (Exo-T) is a biotechnology company dedicated to pre-clinical and clinical development of advanced therapies for skin lesions. Exo-T envisage becoming a company of reference for the use of exosomes as a treatment tool for wound healing. The company is presently developing its first product, Exo-Wound, for the treatment of chronic wounds, which affect millions of people worldwide.
F-star is a leader in the discovery and development of novel bispecific antibodiesF-star is a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics.We are poised to dominate the bispecific antibody space in immuno-oncology through the application of our highly efficient Modular Antibody Technology™ platform.Our powerful platform enables the discovery of novel bispecific antibodies, which are selected for their potential to transform the treatment of cancer. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including: AbbVie, Bristol-Myers Squibb, Merck KGaA and Denali Therapeutics.We have built a comprehensive IP estate around our technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors.F-star currently employs over 80 people at its research site in Cambridge, UK.
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA. This new approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to discover and understand the action of a factor potentially causative of multiple sclerosis, the pathogenic MSRV protein, which is a member of the human endogenous retrovirus-W family (HERV-W). The presence of pathogenic HERV-W in the brains of patients may be an important cause of the inflammatory and neurodegenerative phenomena characterizing this disease.
GeNeuro has developed GNbAC1, a humanized monoclonal antibody, currently in Phase IIb clinical development in multiple sclerosis with the support of Servier, the context of a 362 M€ partnership signed in 2014. By neutralizing the pathogenic HERV-W protein rather than targeting the patient's immune system, GNbAC1 could prove to be both safe and effective, and potentially able to slow or even halt the progression of the disease in all its forms. GeNeuro develops its platform against other autoimmune diseases, such as type 1 diabetes for which a 60-patient Phase lla with GNbAC1 was launched in April 2017, and chronic inflammatory demyelinating polyneuropathy for which a proof-of-concept trial is planned to be launched by end of 2017. To capture the full therapeutic potential of its approach against pathogenic HERV proteins, GeNeuro is developing new therapeutics, currently at preclinical stage, against other pathologies such as inflammatory psychosis, as well as against amyotrophic lateral sclerosis for which GeNeuro has signed a research partnership with the NIH.
GeNeuro SA is a member of the Swiss Biotech Association, a member of the BioAlps community and has the CTI (Commission for Technology and Innovation) start-up label. GeNeuro Innovation SAS is member of the French Lyon Biopole.
Millions of people all over the world suffer from diseases, for which there is no known treatment. At the same time, thousands of skilled scientists are working on early research projects, which might one day provide novel therapies for the people in need.
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson’s and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas.
Herantis’ shares are listed on NASDAQ OMX Helsinki First North Finland.
ILTOO Pharma is a clinical-stage biotechnology company dedicated to the development of biotherapies that have the ability to balance the immune system and revolutionize the treatment of autoimmune and inflammatory disorders (ADs). Based on a deep expertise in translational research and clinical immunology, ILTOO Pharma is pioneering the field of regulatory T cells (Tregs)-mediated immunotherapies.
ILTOO Pharma lead product, ILT-101, is the world most advanced IL-2-based therapies. ILTOO’s vision is that, along with corticosteroids and anti-TNFs antibodies, IL2-mediated immunotherapy will become the next-generation standard of care for treating ADs. Systemic lupus erythematosus (SLE) and recently diagnosed type-1 diabetes (T1D) have been selected as top priority indications. By targeting an immunological imbalance which is the common root cause of ADs, ILT-101 has the potential to bring an enhanced therapeutic benefit to a wide spectrum of patients affected by ADs.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over $315M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology.
LIfT BioSciences is a socially-minded Biotech start-up developing The World's First Cell Bank of Cancer Killing Granulocytes (a type of white blood cell). The Cell Bank will enable us to provide a range of potentially life-saving immuno-oncology cell therapies for different solid tumour types. Our innate immunity platform is known as Neutrophil only Leukocyte Infusion Therapy (N-LIfT), a first-in-class patented cell therapy. N-LIfT is produced ex-vivo and benefits from being more scalable with potentially better and more consistent efficacy and safety than other forms of leukocyte infusion.
LIfT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity. The first targeted indication is pancreatic cancer (pancreatic ductal adenocarcinoma – PDAC), one of the types of cancer with the highest unmet medical need. CRUK report that just 3% of Patients Diagnosed with PDAC survive 5 years. PDAC is classified as an orphan disease by European Medicines Agency (EMA) which will facilitate our market access. The EMA has classified N-LIfT as an Advanced Therapeutic Medicinal Product (ATMP), which sets us up for accelerated approval (early access scheme) and enhanced proprietary protection (market and data exclusivity), subject to trial results. We are currently completing pre-clinical work before running our first in-human clinical trial. The aim is to demonstrate remission in high unmet need solid tumours by 2021, including Pancreatic Cancer. Due to the sensitivity of our work and the IP required to successfully bring this therapy to market we are unable to disclose more at present. If you would like to find out more, or if you would be interested in investing please Contact Us.
Medherant is developing the next generation of patches for local and transdermal delivery of drugs. TEPI Patch. Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel technologies for delivery of drugs via the skin using their world-leading expertise in bioadhesives and polymer chemistry. The Company is based on the University of Warwick Science Park in Coventry (UK). Medherant has received investment from Mercia Fund Management and others. Delivery of drugs using patches that are applied to the skin provides better control of the dose than with gels, ointments and creams. However, the currently available technologies limit the types of drugs that can be used and the quantities that can be loaded into the patch. Medherant’s TEPI Patch® is formulated with a novel polymer adhesive which has been exclusively licensed from Bostik. The drug to be delivered is mixed with the adhesive to form a thin, flexible, single layer patch.
One of the key advantages of the TEPI Patch® technology is that a greater quantity of drug can be blended with the adhesive. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch or reduce patch size. The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. Medherant is developing its own TEPI Patch® products and working with third parties to assess the suitability of the technology for their drugs. The Company expects to earn revenues from licensing products that it has developed to pharmaceutical companies and through collaborative development projects leading to potential technology licences.
Metys Pharmaceuticals is developing dimiracetam for the prevention of chemotherapy-induced painful peripheral neuropathy. In the US alone, in a single year, more than 400'000 patients suffer from the neuropathy caused by their life-saving cancer treatment. No drug has been approved to prevent or treat this condition. Dimiracetam is an orally active, small molecule with more than 200 patients' safety and tolerability data; dimiracetam is highly effective in preventing and treating chemotherapy-induced neuropathy in rodents. Metys Pharmaceuticals is preparing the first dedicated efficacy study of dimiracetam in this indication.
MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company built on a mission to be an international pioneer in Phytocannabinoid-based medicine within the biopharmaceutical industry.
Heralding countless years of practical, scientific and business experience, MGC Pharma’s founders are all prominent leaders in the Medical Cannabis industry.
MGC Pharma’s principal business goal is to produce and supply high quality Cannabinoid based pharmaceutical products for the emergent medical markets in Europe, North America and Australasia.
Walking and breathing are examples of essential human behaviour that is controlled by the nervous system and powered by contractions of skeletal muscles. Neuromuscular disorders refers to a broad range of conditions in which the communication between the central nervous system and skeletal muscle fails, and patients develop debilitating weakness and fatigue.
In patients with neuromuscular disorders the loss of muscle functionality leads to reduced mobility and lack of independence and, in turn, markedly reduced quality of life. In severely affected patients the muscle weakness can lead to life-threatening respiratory problems. Our vision is to improve the quality of life and survival of patients with neuromuscular disorders. To achieve this, NMD Pharma is on a mission to develop novel treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders.
NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic properties generated through their Reverse Translational Medicine™ (RTM™) technology platform.
The founding and management team has a proven track record in research and drug development. Existing collaborations and networks with partners in industry, academia, and the medical community leverage the advancement of our programs.
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics. From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional €18.2M raised from blue chip investors in the US and Europe in March 2017.
With two compounds in clinical trials, ORY-1001, a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase I/IIA in oncology, and ORY-2001, a dual LSD1/MAO-B inhibitor for the treatment of multiple sclerosis, Alzheimer’s disease and other neurodegenerative diseases, in Phase IIA, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications, the company has a broad and growing portfolio. From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of ORY-2001 since the start of our CNS research.
The company has a seasoned executive management with vast experience in the industry.
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*mel, our first drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer. Our approach can be applied to virtually any type of cancer and any patient population, and combined with differents cancer treatments.
Pharmaleads aims to provide patients suffering from severe chronic and acute pain with improved pain relief without the side effects associated with other classes of analgesics. Based on years of experience in the design of highly potent and specific inhibitors of enkephalinases, Pharmaleads has developed a new class of analgesics called DENKIs (Dual Enkephalinases inhibitors). These small molecules are able to provide patients with local and sustainable pain relief.
Pharmaleads’ DENKIs are first-in-class drugs with a novel mechanism of action tackling pain by using endogenous enkephalins, natural peptides that specifically bind to pain-related opioid receptors to naturally modulate pain without the side effects observed with exogenous opioid drugs that also bind to other opioids receptors, not involved in pain control, triggering multiple side effects. Pharmaleads believes its products can change the lives of the many patients who are in need of improved treatment options for their chronic and/or acute pain, and could offer healthcare providers with an improved pain management option that helps address the opioid epidemic.
Selvita is one of the largest drug discovery companies in Europe. The company has two primary focus areas: to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services, and as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.The company was established in 2007 and currently employs over 400 scientists, among which 30% are PhDs.Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and foreign offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK .Our scientists have extensive experience in life sciences, and we offer the following:Contract chemistry servicesBiology servicesIntegrated drug discovery projectsComparative studies of biosimilar medicinal products Selvita’s laboratories are GLP and GMP-certified.Selvita’s internal R&D department focuses on oncology.
The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor, which has entered the clinic in March 2017, and was subsequently licensed to Menarini Group.The second most advanced program is SEL120, a first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer is currently developed in partnership with The Leukemia and Lymphoma Society.Selvita Early Discovery programs include: Immunooncology platform, Epigenetic platform, program targeting metabolic abnormalities in cancer, as well as an early discovery stage programs in the area of protein kinases.The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Merck, H3 Biomedicine, Nodthera Therapeutics, as well as Menarini Group and The Leukemia and Lymphoma Society.Selvita is listed on the Warsaw Stock Exchange (WSE:SLV).
Sensorion is a biopharmaceutical company, formed in 2009, focused as a “pure player” on developing therapies for debilitating inner ear disorders. With our primary strength in the inner ear and neurosciences, we combine world-class scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics. Sensorion was initially founded by French and European academics, and has now diversified its core competencies by recruiting a network of partners and key opinion leaders. Our leadership has exceptional, solid experience in research, marketing and finance.
STALICLA is a mission-driven biotech, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). At STALICLA, we have developed an innovative algorithm platform that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of ASD patients. By identifying these subgroups, we aim to offer repurposed drugs that provide more effective, personalized treatment options. The company was founded in Geneva, Switzerland in May 2017 by today’s CEO Lynn Durham, a biotech entrepreneur with a lifelong involvement with the autism community. STALICLA has established a research partnership with the Greenwood Genetic Center, South Carolina, USA, a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities. We target liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas’ peptide-loaded nanoparticles mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T-cells (Tregs). This allows us to develop novel therapeutic solutions for autoimmune diseases, allergies and anti-drug antibodies.
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens. The Company’s lead product candidate, oral VXM01, currently in clinical trials, activates killer T-cells targeting tumor vasculature and certain immune-suppressive cells and causes increased inflammation in solid tumors. VAXIMM completed a Phase I/II trial of VXM01 in advanced pancreatic cancer. Clinical trials are completed or ongoing in metastatic colorectal cancer and in recurrent glioblastoma (brain cancer).
The Company has several additional product candidates at various stages of preclinical development. These candidates can be developed as stand-alone therapies or in combination with other immunotherapies, including VXM01. Investors in our company include: BB Biotech Ventures, Merck Serono Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland with a wholly owned subsidiary, VAXIMM GmbH (Mannheim, Germany), from where the Company’s development activities are orchestrated, and a laboratory in Regensburg, Germany.